(Total Views: 366)
Posted On: 03/07/2021 4:29:33 PM
Post# of 153963
Jeff
I agree that LH will be a great indication but we don’t know if it will work yet.
We now know it works in a subgroup population of severe COVID patients - but we need to prove it statistically with more patients.
This is our closest to revenue opportunity and we should pursue it.
Warrants incentives or other loan or equity offering (while dilutive - especially with the fife reset are possible)
I assume that you know that is HIV and covid in the US already have sales partners.
The company did correct the bad previous protocols with the exit of the old regime and hire of the new head oF R&D
IMO
I agree that LH will be a great indication but we don’t know if it will work yet.
We now know it works in a subgroup population of severe COVID patients - but we need to prove it statistically with more patients.
This is our closest to revenue opportunity and we should pursue it.
Warrants incentives or other loan or equity offering (while dilutive - especially with the fife reset are possible)
I assume that you know that is HIV and covid in the US already have sales partners.
The company did correct the bad previous protocols with the exit of the old regime and hire of the new head oF R&D
IMO
(0)
(0)
